nach oben

Erschienen in:

14.09.2017 | Epidemiology

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

verfasst von: Kirsten A. Nyrop, Allison M. Deal, Jordan T. Lee, Hyman B. Muss, Seul Ki Choi, Amy Wheless, Lisa A. Carey, Shlomit S. Shachar

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET.

Methods

We conducted a retrospective review of electronic medical records. Descriptive statistics and Chi-squared and t tests were used to compare pre- and postmenopausal women. Chi-squared tests and ANOVA were used for within-group associations between patient characteristics and weight trajectories. Log-binomial regression models were used to estimate relative risk for weight gain.

Results

The final sample was 32% premenopausal (n = 140) and 68% postmenopausal (n = 298). Relative risk (RR) for weight gain during ET was highest in women who were premenopausal (RR = 1.29, 1.03–1.52) and had Stage 3 BC (RR = 2.12, 1.59–2.82), mastectomy (RR = 1.49, 1.19–1.88), axillary node dissection (RR = 1.39, 1.11–1.73), and chemotherapy (RR = 1.80, 1.37–2.36). For each kg of weight gained between BC diagnosis and start of ET, and for each additional year of age, RR of gaining weight during ET decreased (RR = 0.98, 0.97–0.99, and RR = 0.99, 0.98–0.99, respectively). Menopausal status and type of ET were not significant predictors of weight gain. In multivariable analysis, only weight loss between BC diagnosis and start of ET was significant.

Conclusion

The association of weight loss prior to ET and subsequent substantial weight gain during ET warrants further investigation.

Kohler BA, Sherman RL, Howlader N et al (2015) Annual report to the Nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):djv048CrossRefPubMedPubMedCentral

Clarke CA, Keegan TH, Yang J et al (2012) Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 104(14):1094–1101CrossRefPubMedPubMedCentral

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed

Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi:10.1093/jnci/dju055 PubMedPubMedCentral

Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 103(3):250–263CrossRefPubMed

Chen L, Li CI (2015) Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomark Prevent 24(11):1666–1672CrossRef

Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102–1109CrossRefPubMed

Benz CC (2008) Impact of aging on the biology of aging. Crit Rev Oncol Hematol 66(1):65–74CrossRefPubMed

Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014:469251CrossRefPubMedPubMedCentral

10.

Gershuni V, Li YR, Williams AD et al (2017) Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res Treat 163(2):375–381CrossRefPubMed

11.

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6CrossRefPubMedPubMedCentral

12.

Eppenberger-Castori S, Moore DH Jr, Thor AD et al (2002) Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34(11):1318–1330CrossRefPubMed

13.

Schiavon G, Smith IE (2014) Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 16(2):206CrossRefPubMedPubMedCentral

14.

Taylor WC, Muss HB (2010) Recent advances: adjuvant therapy for older women with breast cancer. Cancer J 16(4):289–293CrossRefPubMed

15.

Dowsett M, Cuzick J, Ingle J et al (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509–518CrossRefPubMed

16.

Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209–219CrossRefPubMedPubMedCentral

17.

Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):255–2269CrossRef

18.

Burstein HJ, Lacchetti C, Anderson H et al (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 34(14):1689–1701CrossRefPubMed

19.

Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129CrossRefPubMed

20.

Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN et al (1999) Factors associated with weight gain in women after diagnosis of breast cancer. Women’s healthy eating and living study group. J Am Diet Assoc 99:1212–1221CrossRefPubMed

21.

Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Asso 97(5):519–526, 529; quiz 527–518

22.

Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat 105(2):177–186CrossRefPubMed

23.

Kim SH, Cho YU, Kim SJ (2013) Weight gain and its correlates among breast cancer survivors. Asian Nurs Res 7(4):161–167CrossRef

24.

Irwin ML, McTiernan A, Baumgartner RN, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782CrossRefPubMedPubMedCentral

25.

van den Berg MM, Winkels RM, de Kruif JT et al (2017) Weight change during chemotherapy in breast cancer patients: a meta-analysis. BMC Cancer 17(1):259CrossRefPubMedPubMedCentral

26.

Mortimer J, Behrendt CE (2013) Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis. J Palliat Med 16(9):1130–1134CrossRefPubMed

27.

Sadim M, Xu Y, Selig K et al (2017) Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Cancer 109:872

28.

Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K (2015) Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer. Cancer Epidemiol Biomark Prevent 24(8):1262–1269CrossRef

29.

Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW (2009) The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45:119–126CrossRefPubMed

30.

Makari-Judson G, Judson CH, Mertens WC (2007) Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. Breast 13(3):258–265CrossRef

31.

Vagenas D, DiSipio T, Battistutta D et al (2015) Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15(1):28CrossRefPubMedPubMedCentral

32.

Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134(2):727–734CrossRefPubMed

33.

Sedjo RL, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. J Cancer Surviv 8(3):410–418CrossRefPubMedPubMedCentral

34.

Francini G, Petrioli R, Montagnani A et al (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95(2):153–158CrossRefPubMedPubMedCentral

35.

Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Prac. 8(6):49–57CrossRef

36.

Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 13(5):363–368CrossRefPubMed

37.

Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer–effect of tamoxifen. Breast Cancer Res Treat 22(2):129–132CrossRefPubMed

38.

Han HS, Lee KW, Kim JH et al (2009) Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat 114(1):147–153CrossRefPubMed

39.

Nyrop KA, Deal AM, Lee JT et al (2017) Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review. Breast Cancer Res Treat 162:375–388CrossRefPubMed

40.

Nyrop KA, Williams GR, Muss HB, Shachar SS (2016) Weight gain during adjuvant endocrine treatment for early-stage breast cancer: what is the evidence? Breast Cancer Res Treat 158(2):203–217CrossRefPubMed

41.

Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30(18):2232–2239CrossRefPubMedPubMedCentral

42.

Kritchevsky SB, Wilcosky TC, Morris DL, Truong KN, Tyroler HA (1991) Changes in plasma lipid and lipoprotein cholesterol and weight prior to the diagnosis of cancer. Can Res 51(12):3198–3203

43.

McTiernan A, Sorensen B, Irwin ML et al (2007) Exercise effect on weight and body fat in men and women. Obesity 15(6):1496–1512CrossRefPubMed

44.

Myers CA, Slack T, Martin CK, Broyles ST, Heymsfield SB (2016) Change in obesity prevalence across the United States is influenced by recreational and healthcare contexts, food environments, and hispanic populations. PLoS ONE 11(2):e0148394CrossRefPubMedPubMedCentral

45.

Vassar M, Holzmann M (2013) The retrospective chart review: important methodological considerations. J Educ Eval Health Prof 10:12CrossRefPubMed

46.

Lee MK, Varzi LA, Chung DU et al (2015) The effect of young age in hormone receptor positive breast cancer. Biomed Res Int 2015:325715PubMedPubMedCentral

47.

Chollet-Hinton L, Anders CK, Tse CK et al (2016) Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina breast cancer study: a case-control study. Breast Cancer Res 18(1):79CrossRefPubMedPubMedCentral

48.

Coughlin SS, Smith SA (2015) The insulin-like growth factor axis, adipokines, physical activity, and obesity in relation to breast cancer incidence and recurrence. Cancer Clin Oncol 4(2):24–31PubMedPubMedCentral

49.

Keum N, Greenwood DC, Lee DH et al (2015) Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 107(2):djv088CrossRefPubMed

50.

Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A (2012) Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS ONE 7(12):e51446CrossRefPubMedPubMedCentral

51.

Biglia N, Peano E, Sgandurra P et al (2013) Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol 29(3):263–267CrossRefPubMed

52.

Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomark Prevent 14(7):1686–1691CrossRef

53.

Ewertz M, Jensen MB, Gunnarsdottir KA et al (2011) Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 29(1):25–31CrossRefPubMed

54.

Litton JK, Gonzalez-Angulo AM, Warneke CL et al (2008) Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol 26(25):4072–4077CrossRefPubMed

55.

Caan BJ, Emond JA, Su HI et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 30(13):1492–1497CrossRefPubMedPubMedCentral

56.

Su H, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211CrossRefPubMedPubMedCentral

57.

Glaus A, Boehme C, Thurlimann B et al (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17(5):801–806CrossRefPubMed

58.

Alfano CM, McGregor BA, Kuniyuki A et al (2006) Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psychooncology. 15(11):985–1000CrossRefPubMedPubMedCentral

59.

Young A, Weltzien E, Kwan M, Castillo A, Caan B, Kroenke CH (2014) Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors. J Cancer Surviv 8(4):539–547CrossRefPubMedPubMedCentral

60.

Imayama I, Alfano CM, Neuhouser ML et al (2013) Weight, inflammation, cancer-related symptoms and health related quality of life among breast cancer survivors. Breast Cancer Res Treat 140(1):159–176CrossRefPubMedPubMedCentral

61.

Befort CA, Austin H, Klemp JR (2011) Weight control needs and experiences among rural breast cancer survivors. Psychooncology. 20(10):1069–1075CrossRefPubMed

62.

Sestak I, Cuzick J, Sapunar F et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 9(9):866–872CrossRefPubMed

63.

Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH (2013) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. The Breast J. 20(1):22–28CrossRefPubMed

64.

Cespedes Feliciano EM, Kwan ML, Kushi LH et al (2017) Body mass index, PAM50 subtype, recurrence and survival among patients with nonmetastatic breast cancer. Cancer 123:2535–2542CrossRefPubMed

65.

Dignam JJ, Wieand K, Johnson KA et al (2006) Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat 97(3):245–254CrossRefPubMed

66.

Kamineni A, Anderson ML, White E et al (2013) Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control 24(2):305–312CrossRefPubMed

67.

Minicozzi P, Berrino F, Sebastiani F et al (2013) High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. Eur J Cancer 49(18):3881–3888CrossRefPubMed

68.

Petrelli JM, Calle EE, Rodriguez C, Thun MJ (2002) Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13(4):325–332CrossRefPubMed

69.

Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer 118(23):5937–5946CrossRefPubMedPubMedCentral

70.

Fedele P, Orlando L, Schiavone P et al (2014) BMI variation increases recurrence risk in women with early-stage breast cancer. Future Oncol. 10(15):2459–2468CrossRefPubMed

71.

Nechuta S, Chen WY, Cai H et al (2016) A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138(9):2088–2097CrossRefPubMed

72.

Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378CrossRefPubMed

73.

Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L (2009) Holmes MD, al. e. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409CrossRefPubMedPubMedCentral

74.

Wolin KY, Schwartz AL, Matthews CE, Courneya KS, Schmitz KH (2012) Implementing the exercise guidelines for cancer survivors. J Support Oncol. 10(5):171–177CrossRefPubMedPubMedCentral

75.

Santa Mina D, Alibhai SM, Matthew AG et al (2012) Exercise in clinical cancer care: a call to action and program development description. Curr Oncol. 19(3):e136–e144CrossRefPubMedPubMedCentral

76.

Ruiz-Casado A, Lucia A (2014) The time has come for oncologists to recommend physical activity to cancer survivors. Arch Exerc Health Dis. 4(1):214–215

Titel: Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
verfasst von: Kirsten A. Nyrop
Allison M. Deal
Jordan T. Lee
Hyman B. Muss
Seul Ki Choi
Amy Wheless
Lisa A. Carey
Shlomit S. Shachar
Publikationsdatum: 14.09.2017
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4501-4

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Association of the severity of diabetes-related complications with stage of breast cancer at diagnosis among elderly women with pre-existing diabetes

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

Predictive role of loco-regional radiotherapy among metastatic breast cancer patients who had undergone primary tumor surgery

Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie